Deals Shaping The Medical Industry, October 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.
You may also be interested in...
Two $1bn+ alliances were penned in April. Vertex and Obsidian entered into an agreement surrounding the discovery of therapies that regulate gene editing for the treatment of serious diseases. Obsidian is eligible for up to $75m in up-front payments and research milestones and could get another $1.3bn in potential milestone payments across up to five potential programs. Artios signed a three-year global research collaboration with Novartis to discover and validate next-generation DNA damage response targets to enhance Novartis’ radioligand therapies. In the top April M&A by deal value, Thermo Fisher and publicly traded contract research organization PPD announced a definitive agreement under which Thermo Fisher will pay $47.50 per share (a 23% premium to the 10-day pre-announcement average) in cash for PPD, for a purchase price of $17.4bn plus the assumption of approximately $3.5bn of net debt. Financing reached $14.6bn in biopharma, $1.2bn in device, and $2.4bn in diagnostics.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
During Q1, biopharma merger and acquisition value reached $34.8bn and drew in $35bn in potential deal value (PDV) from alliances. Device company M&A values reached $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.